Literature DB >> 12354344

Pharmacologic treatment for detrusor overactivity.

H Henry Lai1, Timothy B Boone, Rodney A Appell.   

Abstract

Recent pharmacologic treatment for detrusor overactivity has resulted in more favorable side effect profiles, not only because of the use of different drug delivery systems for older drugs but perhaps also due to the improved bladder selectivity of newer antimuscarinic agents. These developments translate into higher patient compliance and better long-term results with the newer agents over generic immediate-release oxybutynin for the treatment of the overactive bladder.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12354344     DOI： 10.1007/s11934-002-0078-4

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  48 in total

1.  Visual hallucinations at the onset of tolterodine treatment in a patient with a high-level spinal cord injury.

Authors:  B Malavaud; H Bagheri; J M Senard; J P Sarramon
Journal:  BJU Int       Date:  1999-12       Impact factor: 5.588

2.  Modern pharmacotherapy of urge urinary incontinence in the USA: tolterodine and oxybutynin.

Authors:  E S Rovner; A J Wein
Journal:  BJU Int       Date:  2000-10       Impact factor: 5.588

3.  Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.

Authors:  G Larsson; B Hallén; L Nilvebrant
Journal:  Urology       Date:  1999-05       Impact factor: 2.649

4.  Low dose oxybutynin for the unstable bladder.

Authors:  J Malone-Lee; D Lubel; G Szonyi
Journal:  BMJ       Date:  1992-04-18

5.  Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group.

Authors:  E Versi; R Appell; D Mobley; W Patton; D Saltzstein
Journal:  Obstet Gynecol       Date:  2000-05       Impact factor: 7.661

6.  Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis.

Authors:  M Lawrence; D R Guay; S R Benson; M J Anderson
Journal:  Pharmacotherapy       Date:  2000-04       Impact factor: 4.705

7.  Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.

Authors:  M A Harvey; K Baker; G A Wells
Journal:  Am J Obstet Gynecol       Date:  2001-07       Impact factor: 8.661

8.  A new questionnaire to assess the quality of life of urinary incontinent women.

Authors:  C J Kelleher; L D Cardozo; V Khullar; S Salvatore
Journal:  Br J Obstet Gynaecol       Date:  1997-12

9.  Dose-ranging study of tolterodine in patients with detrusor hyperreflexia.

Authors:  P E Van Kerrebroeck; G Amarenco; J W Thüroff; H G Madersbacher; M T Lock; E J Messelink; J M Soler
Journal:  Neurourol Urodyn       Date:  1998       Impact factor: 2.696

10.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

Authors:  P Abrams; R Freeman; C Anderström; A Mattiasson
Journal:  Br J Urol       Date:  1998-06
View more
  2 in total

Review 1.  The impact of detrusor overactivity on the management of stress urinary incontinence in women.

Authors:  H Henry Lai; Michael Simon; Timothy B Boone
Journal:  Curr Urol Rep       Date:  2006-09       Impact factor: 2.862

2.  Oxybutynin: an overview of the available formulations.

Authors:  Rebecca J McCrery; Rodney A Appell
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.